87 related articles for article (PubMed ID: 12865039)
1. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
BENEDICT Group
Control Clin Trials; 2003 Aug; 24(4):442-61. PubMed ID: 12865039
[TBL] [Abstract][Full Text] [Related]
2. Barriers to clinical research participation in a diabetes randomized clinical trial.
Robiner WN; Yozwiak JA; Bearman DL; Strand TD; Strasburg KR
Soc Sci Med; 2009 Mar; 68(6):1069-74. PubMed ID: 19167143
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
Remuzzi G; Macia M; Ruggenenti P
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
[TBL] [Abstract][Full Text] [Related]
4. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.
Ruggenenti P; Fassi A; Ilieva A; Iliev IP; Chiurchiu C; Rubis N; Gherardi G; Ene-Iordache B; Gaspari F; Perna A; Cravedi P; Bossi A; Trevisan R; Motterlini N; Remuzzi G;
J Hypertens; 2011 Feb; 29(2):207-16. PubMed ID: 21243736
[TBL] [Abstract][Full Text] [Related]
5. Preventing microalbuminuria in type 2 diabetes.
Ruggenenti P; Fassi A; Ilieva AP; Bruno S; Iliev IP; Brusegan V; Rubis N; Gherardi G; Arnoldi F; Ganeva M; Ene-Iordache B; Gaspari F; Perna A; Bossi A; Trevisan R; Dodesini AR; Remuzzi G;
N Engl J Med; 2004 Nov; 351(19):1941-51. PubMed ID: 15516697
[TBL] [Abstract][Full Text] [Related]
6. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
[TBL] [Abstract][Full Text] [Related]
7. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B
Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial.
Fuchs FD; Scala LC; Vilela-Martin JF; de Mello RB; Mosele F; Whelton PK; Poli-de-Figueiredo CE; de Alencastro PR; E Silva RP; Gus M; Bortolotto LA; Schlatter R; Cesarino EJ; Castro I; Neto JA; Chaves H; Steffens AA; Alves JG; Brandão AA; de Sousa MR; Jardim PC; Moreira LB; Franco RS; Gomes MM; Neto AA; Fuchs FC; Filho DC; Nóbrega AC; Nobre F; Berwanger O; Fuchs SC
J Hypertens; 2016 Apr; 34(4):798-806. PubMed ID: 26938814
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
[TBL] [Abstract][Full Text] [Related]
10. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol.
London GM; Asmar RG; O'Rourke MF; Safar ME;
J Am Coll Cardiol; 2004 Jan; 43(1):92-9. PubMed ID: 14715189
[TBL] [Abstract][Full Text] [Related]
11. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
[TBL] [Abstract][Full Text] [Related]
12. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Anker SD; Agarwal R; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Schloemer P; Tornus I; Joseph A; Bakris GL;
Circulation; 2021 Feb; 143(6):540-552. PubMed ID: 33198491
[TBL] [Abstract][Full Text] [Related]
13. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
[TBL] [Abstract][Full Text] [Related]
14. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
[TBL] [Abstract][Full Text] [Related]
15. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Cosentino F; Grant PJ; Aboyans V; Bailey CJ; Ceriello A; Delgado V; Federici M; Filippatos G; Grobbee DE; Hansen TB; Huikuri HV; Johansson I; Jüni P; Lettino M; Marx N; Mellbin LG; Östgren CJ; Rocca B; Roffi M; Sattar N; Seferović PM; Sousa-Uva M; Valensi P; Wheeler DC;
Eur Heart J; 2020 Jan; 41(2):255-323. PubMed ID: 31497854
[No Abstract] [Full Text] [Related]
16. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
[TBL] [Abstract][Full Text] [Related]
17. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
[TBL] [Abstract][Full Text] [Related]
18. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
19. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure control for diabetic retinopathy.
Do DV; Han G; Abariga SA; Sleilati G; Vedula SS; Hawkins BS
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD006127. PubMed ID: 36975019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
